More on UNCY
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.46 |
|
|||
| Open | $5.50 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $5.59 | ||||
| Day Low | $5.31 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 339,395 | ||||
- Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC
- Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
- Form 8-K Unicycive Therapeutics, For: Jul 02
- UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton
- Form 144 Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
- Unicycive Therapeutics (UNCY) PT Lowered to $13 at Benchmark on OLC Rejection
- Increasing unusual option volume: UNM CGNX UNCY CNXC NN DOMO JACK SOLS KSTR
- FDA issues second complete response letter to Unicycive over OLC drug application
- Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
- H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
Entities mentioned with UNCY
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
